JanOne is a biotechnology company dedicated to developing treatments for diseases that cause severe pain, with a mission to reduce the reliance on opioid prescriptions. Their focus is on treating conditions such as Peripheral Artery Disease (PAD), which affects millions of Americans and poses a risk for addiction when opioids are used for pain management. JanOne aims to bring non-addictive solutions to the market and is currently advancing their treatment for PAD through Phase 2b trials.
With a commitment to treating pain at its source, JanOne aims to provide relief for chronic and neuropathic pain caused by various conditions. By offering drugs with non-addictive pain-relieving properties, the company strives to reduce the need for dangerous opioid drugs. JanOne's first drug candidate targets PAD, a condition that affects a significant number of individuals in the US and can cause severe pain. As a pharmaceutical company, JanOne trades on the NASDAQ under the symbol JAN and operates independently alongside its subsidiary business, Appliance Recycling Centers of America, Inc (ARCA).
Generated from the website